Biotechs seek treasure in pharma castoff, antibiotics

Antibiotics lack the revenue luster to keep pharma engaged, and only three have been approved by the FDA since 2006. But the niche looks good to some biotechs. "A smaller, more manageable product with revenue under $1 billion is fine for a biotech company," Needham & Co. analyst Alan Carr tells Bloomberg. Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.